PCRX

Pacira BioSciences, Inc.
$23.35
-0.13 (-0.55%)
Mkt Cap 918.47M
Volume 852,381
52W Range 18.8-27.64
Sector Healthcare
Beta 0.32
EPS (TTM) 0.12
P/E Ratio 191.24
Revenue (TTM) 734.86M
Rev Growth (5Y) +11.1%
EPS Growth (5Y) -45.8%
AlphaVal · Fair Value
$37.05
Undervalued · Moderate
37.0% below fair value
AlphaQuality · Grade
C-
Platform & Compounding FCF
44.8 / 100 composite

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 726.41M 700.97M 674.98M 666.82M 541.53M 429.65M 421.03M 337.28M 286.63M 276.37M 249.00M 197.67M
Net Income 7.03M (99.56M) 41.95M 15.91M 41.98M 145.52M (11.02M) (471,000) (42.61M) (37.95M) 1.86M (13.72M)
EPS 0.16 -2.15 0.91 0.35 0.95 3.41 -0.27 -0.01 -1.07 -1.02 0.05 -0.39
Free Cash Flow 136.66M 178.75M 139.49M 115.20M 79.85M 39.23M 60.36M 34.36M (1.48M) 8.74M N/A N/A
FCF / Share 3.07 3.87 3.02 2.53 1.80 0.92 1.45 0.84 -0.04 0.24 N/A N/A
Operating CF 151.99M 189.39M 154.65M 145.27M 125.72M 77.03M 70.52M 48.87M 17.79M 33.45M N/A N/A
Total Assets 1.26B 1.55B 1.57B 1.68B 2.08B 1.27B 831.07M 689.35M 628.37M 391.47M N/A N/A
Total Debt 454.38M 638.85M 586.04M 763.39M 1.13B 541.13M 351.92M 290.93M 276.50M 108.74M N/A N/A
Cash & Equiv 158.54M 276.77M 153.30M 104.14M 585.58M 99.96M 78.23M 132.53M 54.13M 35.94M N/A N/A
Book Value 693.11M 778.35M 870.13M 775.01M 730.41M 619.69M 354.94M 321.23M 279.48M 218.98M N/A N/A
Return on Equity 0.01 -0.13 0.05 0.02 0.06 0.23 -0.03 -0.00 -0.15 -0.17 N/A N/A
PCRX News
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
May 21, 2026 09:53 AM · prnewswire.com
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
May 20, 2026 08:28 AM · prnewswire.com
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
May 20, 2026 02:30 AM · globenewswire.com
Pacira BioSciences: Exparel Still Supports My Original Bull Case
May 19, 2026 04:00 AM · seekingalpha.com
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualif
May 13, 2026 07:00 AM · gurufocus.com
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
May 13, 2026 06:58 AM · prnewswire.com
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
May 13, 2026 04:00 AM · globenewswire.com
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
May 12, 2026 12:01 PM · globenewswire.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026 04:00 AM · globenewswire.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026 04:00 AM · globenewswire.com